Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucose-6-phosphate isomerase (GPI) is an enzyme that catalyzes the reversible interconversion of D-glucose-6-phosphate and D-fructose-6-phosphate, a critical step in glycolysis and gluconeogenesis. Beyond its metabolic function, GPI exhibits moonlighting activities, acting as an angiogenic factor, neuroleukin (a neurotrophic factor), and autocrine motility factor promoting cancer cell metastasis. Mutations in GPI can cause glucose phosphate isomerase deficiency, leading to hemolytic anemia and neurological symptoms. In cancer, its overexpression/secretion promotes tumor metastasis.
Acid/base catalysis: His388 protonates the C5 oxygen; Lys518 deprotonates C1 hydroxyl to open glucose’s ring structure. Substrate rotates about C3-C4; Glu357 abstracts a proton from C2 forming a cis-enediol intermediate stabilized by Arg272. Proton transfer completes conversion to fructose 6-phosphate; substrate ring closes via further rotation and deprotonation by Lys518.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucose-6-phosphate Isomerase (GPI).